Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells

Cytotherapy

Volumn 13, Issue 6, 2011, Pages 739-752

  Flechsig, Christin ^a   Suezer, Yasemin ^b   Kapp, Markus ^a   Tan, Sen Mui ^a   Löffler, Jürgen ^a   Sutter, Gerd ^c   Einsele, Hermann ^a   Grigoleit, Goetz Ulrich ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

allogeneic stem cell transplantation; antigen presenting cells; dendritic cells; modified vaccinia Ankara; vaccine

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMEDIATE EARLY PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 1BETA; INTERLEUKIN 6; MODIFIED VACCINIA VIRUS ANKARA VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INFECTION RATE; LEUKOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MODIFIED VACCINIA ANKARA VIRUS INFECTION; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; VIRUS INFECTION;

EID: 79959198504     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2010.549123     Document Type: Article

References (61)

1. Mayr A, Hochstein-MintzeI V, Stickl H. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection. 1975;3:6-14.
2. Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology. 1997;238:198-211. (Pubitemid 28218138)
3. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol. 1998;79:347-52. (Pubitemid 28048439)
4. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol. 1991;72:1031-8.
5. Altenburger W, Suter CP, Altenburger J. Partial deletion of the human host range gene in the attenuated vaccinia virus MVA. Arch Virol. 1989;105:15-27. (Pubitemid 19128945)
6. Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology. 1998;244:365-96. (Pubitemid 28384101)
7. Mayr A, Danner K. Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand. 1978;41: 225-34. (Pubitemid 9104710)
8. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author transl)]. Dtsch Med Wochenschr. 1974;99:2386-92.
9. Mayr A, Stickl H, Muller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author transl)]. Zentralbl Bakteriol [B]. 1978;167:375-90. (Pubitemid 9145179)
10. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA. 1992;89:10847-51.
11. Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T, et al. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine. 2008;26: 6883-93.
12. Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine. 2007;25:2120-7. (Pubitemid 46237679)
13. Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, et al. Phase II trial of modified vaccinia Ankara (MVA) virus expressing 5T4 and high dose interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med. 2009;7:2.
14. Dreicer R, Ahman R, Pantuck A, Stadler WM, Bizouarne N, Derbij BA, et al. Vaccine immunotherapy with MVA-Muc1- IL2 (TG4010) in prostate cancer patients with biochemical failure. ASCO Annual Meeting Proceedings. J Clin Oncol. 2005;23:4581.
15. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother. 2008; 57:977-86.
16. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Levy E, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol. 2008;3:735-44.
17. Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, et al. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modifi ed vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother. 2005;54:453-67. (Pubitemid 40543685)
18. Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis. 2008;198:544-52.
19. Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, Hill H, et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine. 2007;25:8562-73. (Pubitemid 350192042)
20. Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine. 2007;25:1513-25. (Pubitemid 46074296)
21. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature. 2004;428:182-5. (Pubitemid 38374314)
22. Cosma A, Nagaraj R, Staib C, Diemer C, Wopfner F, Schatzl H, et al. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. AIDS Res Hum Retroviruses. 2007;23:782-93. (Pubitemid 47047917)
23. Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG, et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine. 2001;19:3700-9. (Pubitemid 32522768)
24. Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, et al. Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine. 2009;27:4468-74.
25. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001;292:69-74.
26. Chahroudi A, Chavan R, Kozyr N, Waller EK, Silvestri G, Feinberg MB. Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J Virol. 2005;79:10397-407. (Pubitemid 41098580)
27. Sanchez-Puig JM, Sanchez L, Roy G, Blasco R. Susceptibility of different leukocyte cell types to vaccinia virus infection. Virol J. 2004;1:10.
28. Liu L, Chavan R, Feinberg MB. Dendritic cells are preferentially targeted among hematolymphocytes by modified vaccinia virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol. 2008;9:15.
29. Drillien R, Spehner D, Hanau D. Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J Gen Virol. 2004;85:2167-75. (Pubitemid 39162587)
30. Guerra S, Najera JL, Gonzalez JM, Lopez-Fernandez LA, Climent N, Gatell JM, et al. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol. 2007;81:8707-21. (Pubitemid 47242844)
31. Lehmann MH, Kastenmuller W, Kandemir JD, Brandt F, Suezer Y, Sutter G. Modified vaccinia virus Ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J Virol. 2009;83:2540-52.
32. Dietz AB, Bulur PA, Emery RL, Winters JL, Epps DE, Zubair AC, et al. A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion. 2006;46:2083-9.
33. Strasser EF, Weidinger T, Zimmermann R, Ringwald J, Eckstein R. Recovery of white blood cells and platelets from leukoreduction system chambers of Trima Accel and COBE Spectra plateletpheresis devices. Transfusion. 2007;47: 1943-5.
34. Neron S, Thibault L, Dussault N, Cote G, Ducas E, Pineault N, et al. Characterization of mononuclear cells remaining in the leukoreduction system chambers of apheresis instruments after routine platelet collection: a new source of viable human blood cells. Transfusion. 2007;47:1042-9.
35. Grigoleit GU, Kapp M, Hebart H, Fick K, Beck R, Jahn G, et al. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor. J Infect Dis. 2007;196:699-704. (Pubitemid 47293851)
36. Staib C, Drexler I, Ohlmann M, Wintersperger S, Erfle V, Sutter G. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques. 2000;28: 1137-42, 44-6, 48.
37. Wyatt LS, Shors ST, Murphy BR, Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine. 1996;14:1451-8. (Pubitemid 27008261)
38. Staib C, Lowel M, Erfle V, Sutter G. Improved host range selection for recombinant modified vaccinia virus Ankara. Biotechniques. 2003;34:694-6, 8, 700.
39. Falkner FG, Moss B. Transient dominant selection of recombinant vaccinia viruses. J Virol. 1990;64:3108-11. (Pubitemid 20171312)
40. Loeffler J, Swatoch P, Akhawi-Araghi D, Hebart H, Einsele H. Automated RNA extraction by MagNA Pure followed by rapid quantification of cytokine and chemokine gene expression with use of fluorescence resonance energy transfer. Clin Chem. 2003;49:955-8. (Pubitemid 36623477)
41. Mezger M, Kneitz S, Wozniok I, Kurzai O, Einsele H, Loeffler J. Proinflammatory response of immature human dendritic cells is mediated by dectin-1 after exposure to Aspergillus fumigatus germ tubes. J Infect Dis. 2008;197:924-31. (Pubitemid 351417017)
42. + T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102: 2892-900.
43. La Rosa C, Wang Z, Lacey SF, Lalimarmo MM, Krishnan A, Longmate J, et al. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. Exp Hematol. 2006;34:497-507.
44. Gasteiger G, Kastenmuller W, Ljapoci R, Sutter G, Drexler I. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol. 2007;81:11925-36. (Pubitemid 47623824)
45. Greiner S, Humrich JY, Thuman P, Sauter B, Schuler G, Jenne L. The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin Exp Immunol. 2006;146:344-53. (Pubitemid 44581351)
46. Ramirez JC, Gherardi MM, Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B-and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol. 2000;74:923-33. (Pubitemid 30036229)
47. Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, Akira S, et al. Innate immune sensing of modifi ed vaccinia virus Ankara (MVA) is mediated by TLR2- TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog. 2009;5:e1000480.
48. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112:1557-69.
49. Snijders A, Hilkens CM, van der Pouw Kraan TC, Engel M, Aarden LA, Kapsenberg ML. Regulation of bioactive IL-12 production in lipopolysaccharide- stimulated human monocytes is determined by the expression of the p35 subunit. J Immunol. 1996;156:1207-12. (Pubitemid 26048118)
50. Kalinski P, Vieira PL, Schuitemaker JH, de Jong EC, Kapsenberg ML. Prostaglandin E(2) is a selective inducer of interleukin- 12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood. 2001;97: 3466-9.
51. Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hollfelder K, et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol. 1995;154:116-27.
52. Mattner F, Fischer S, Guckes S, Jin S, Kaulen H, Schmitt E, et al. The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur J Immunol. 1993;23:2202-8. (Pubitemid 23265883)
53. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715-25.
54. Romagnani P, Maggi L, Mazzinghi B, Cosmi L, Lasagni L, Liotta F, et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol. 2005;116:1372-9. (Pubitemid 41740951)
55. Boraschi D, Villa L, Volpini G, Bossu P, Censini S, Ghiara P, et al. Differential activity of interleukin 1 alpha and interleukin 1 beta in the stimulation of the immune response in vivo. Eur J Immunol. 1990;20:317-21. (Pubitemid 20082399)
56. Johnson VJ, Yucesoy B, Luster MI. Prevention of IL-1 signaling attenuates airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J Allergy Clin Immunol. 2005;116:851-8. (Pubitemid 41400551)
57. Wang CC, Fu CL, Yang YH, Lo YC, Wang LC, Chuang YH, et al. Adenovirus expressing interleukin-1 receptor antagonist alleviates allergic airway inflammation in a murine model of asthma. Gene Ther. 2006;13:1414-21.
58. Annunziato F, Romagnani S. Do studies in humans better depict Th17 cells? Blood. 2009;114:2213-9.
59. Kastenmuller W, Drexler I, Ludwig H, Erfle V, Peschel C, Bernhard H, et al. Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct matura tion-dependent cytopathogenicity. Virology. 2006;350: 276-88. (Pubitemid 43928113)
60. Baixeras E, Cebrian A, Albar JP, Salas J, Martinez AC, Vinuela E, et al. Vaccinia virus-induced apoptosis in immature B lymphocytes: role of cellular Bcl-2. Virus Res. 1998; 58:107-13. (Pubitemid 28546727)
61. Norder M, Becker PD, Drexler I, Link C, Erfle V, Guzman CA. Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model. PLoS One.5: e11400.